Literature DB >> 9715593

Why multidrug therapy for multibacillary leprosy can be shortened to 12 months.

B Ji.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715593     DOI: 10.5935/0305-7518.19980009

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


× No keyword cloud information.
  4 in total

1.  Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.

Authors:  E Cambau; P Saunderson; M Matsuoka; S T Cole; M Kai; P Suffys; P S Rosa; D Williams; U D Gupta; M Lavania; N Cardona-Castro; Y Miyamoto; D Hagge; A Srikantam; W Hongseng; A Indropo; V Vissa; R C Johnson; B Cauchoix; V K Pannikar; E A W D Cooreman; V R R Pemmaraju; L Gillini
Journal:  Clin Microbiol Infect       Date:  2018-03-01       Impact factor: 8.067

2.  Fixed-duration therapy in leprosy: limitations and opportunities.

Authors:  Munisamy Malathi; Devinder Mohan Thappa
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

3.  Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study.

Authors:  Anil Kumar; Anita Girdhar; B K Girdhar
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

4.  World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.

Authors:  Maria Lazo-Porras; Gabriela J Prutsky; Patricia Barrionuevo; Jose Carlos Tapia; Cesar Ugarte-Gil; Oscar J Ponce; Ana Acuña-Villaorduña; Juan Pablo Domecq; Celso De la Cruz-Luque; Larry J Prokop; Germán Málaga
Journal:  BMC Infect Dis       Date:  2020-01-20       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.